GSK · Pharma and healthcare · one day
GSK (GSK): news on Friday 30 October 2026
News from the 24 hours to Friday morning, 30 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on mixed third-quarter results, falling vaccine sales and a share price pullback, with Jefferies downgrading and other brokers trimming targets. Partly offsetting this were two US regulatory approvals, a Strep A vaccine collaboration and a reaffirmed outlook.
What drove it
- Q3 results and vaccine sales
- analyst downgrades
- FDA approvals
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
| Tue 27 Oct | +9.3 | 29 |
| Wed 28 Oct | +7.0 | 23 |
| Thu 29 Oct | −6.3 | 77 |
| Fri 30 Oct | −3.7 | 21 |
10 stories · 21 headlines · strongest first
Pharma and healthcare on 30 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK reports third-quarter results, keeps 2026 outlook; shares fall on vaccines −2.95 headlines today · 82 in all, since 24 October · Coverage of GSK's third-quarter results notes the reaffirmed outlook, lower vaccine sales and pressure on margins. | ||
| −10.0 | Share price fell on declining vaccine revenue. | |
| −6.7 | Earnings expected to be pressured by narrowing profit margins. | |
| +4.2 | Company confirmed guidance and a deep late-stage pipeline, despite downgrade. | |
| +3.3 | Results coverage noting HIV product expansion opportunity. | |
| 0.0 | Results preview weighing new launches against older drug pressure. | |
| GSK share price moves and technical views −2.74 headlines today · 10 in all, since 24 October · Pieces report GSK shares falling and weak momentum. | ||
| −6.7 | Shares dropping amid persistently weak momentum. | |
| −5.8 | Analyst expects limited profit growth ahead. | |
| −5.8 | Share price decline drawing attention. | |
| −5.8 | Modest share price decline. | |
| Jefferies lowers GSK rating to Hold −7.83 headlines today · Jefferies moved GSK from Buy to Hold and reduced its price target. | ||
| −8.3 | Broker moves to a less positive rating and cuts target. | |
| −8.3 | Broker downgrade with lower price target. | |
| −6.7 | Broker downgrade featured in ratings roundup. | |
| RBC trims GSK price target to 1,925p −2.92 headlines today · RBC adjusted its model after mixed results and lowered its target while keeping Sector Perform. | ||
| −4.2 | Small target reduction, rating unchanged. | |
| −1.7 | Broker adjusts estimates after results it called mixed. | |
| Brokers rate GSK +0.62 headlines today · 12 in all, since 22 October · UBS stayed Neutral and another source noted a maintained Buy rating on GSK. | ||
| −1.7 | Analyst keeps positive stance but flags weaker quarterly vaccine performance. | |
| 0.0 | Broker holds a middling rating. | |
| FDA clears Hibsago, GSK's medicine for chronic hepatitis B +10.01 headline today · 47 in all, since 21 October · A report covers the FDA approval of Hibsago. | ||
| +10.0 | US regulator clears new hepatitis B treatment, adding a product. | |
| GSK reports Jemperli rectal cancer trial results +10.01 headline today · 9 in all, since 25 October · A report covers FDA approval of Jemperli for selected rectal cancer patients. | ||
| +10.0 | Regulatory clearance of an existing drug for a new cancer indication. | |
| MHRA and GSK develop Strep A vaccine +6.71 headline today · The MHRA and GSK are jointly working on a Strep A vaccine. | ||
| +6.7 | Collaboration with UK regulator on a new vaccine candidate. | |
| GSK analysis on growth outlook +1.71 headline today · A Seeking Alpha piece assesses GSK's prospects. | ||
| +1.7 | Analyst view recognises momentum while warning of upcoming obstacles. | |
| GSK compared with Moderna 0.01 headline today · A comparison asks which of GSK and Moderna offers more growth. | ||
| 0.0 | Comparison article with no clear verdict on the company. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.